D-Day For KPTI Today

Karyopharm Therapeutics Inc. is slated to provide an overview of top-line results from its phase 2b study of oral Selinexor in multiple myeloma, dubbed STORM, today.

from RTT - Biotech http://ift.tt/2bPHGnb
via IFTTT